There are 2185 resources available
432P - Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician’s choice in HER2-low, hormone receptor–positive metastatic breast cancer in DESTINY-Breast04
Presenter: Naoto Ueno
Session: Poster session 15
Resources:
Abstract
1522P - S-1 monotherapy versus nanoliposomal irinotecan plus 5-fluorouracil/leucovorin regimen for second-line therapy of recurrent or metastatic pancreatic cancer (JON 2109-P)
Presenter: Yuichiro Tozuka
Session: Poster session 18
Resources:
Abstract
433TiP - Phase III, randomized, open-label TroFuse-010 Study of sacituzumab tirumotecan (sac-TMT) alone and with pembrolizumab vs treatment of physician’s choice chemotherapy (TPC) in patients with HR+/HER2- unresectable locally advanced or metastatic breast cancer (mBC)
Presenter: Sara Tolaney
Session: Poster session 15
Resources:
Abstract
1523P - Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
Presenter: Yasin Sezgin
Session: Poster session 18
Resources:
Abstract
434TiP - ALTER-BC-Ib-01: A prospective phase Ib study of anlotinib with trastuzumab deruxtecan (T-DXd) for HER2-low unresectable (u)/metastatic (m) breast cancer (BC)
Presenter: Yanchun Meng
Session: Poster session 15
Resources:
Abstract
1524P - Preliminary phase I safety and activity of IMM-1-104, an orally dosed universal RAS inhibitor that drives deep cyclic inhibition of the MAPK pathway at MEK, in patients with advanced unresectable or metastatic solid tumors
Presenter: Vincent Chung
Session: Poster session 18
Resources:
Abstract
435TiP - Molecular imaging of programmed death ligand 1 (PD-L1) expression with [89Zr]Zr-atezolizumab positron emission tomography/computed tomography (PET/CT) in patients with metastatic triple negative breast cancer (mTNBC): The MIMIR-study
Presenter: Renske Altena
Session: Poster session 15
Resources:
Abstract
1525P - Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study
Presenter: Jens Siveke
Session: Poster session 18
Resources:
Abstract
436TiP - DYNASTY-Breast02: A phase III trial of BNT323/DB-1303 vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer
Presenter: Joyce O'Shaughnessy
Session: Poster session 15
Resources:
Abstract
1526P - Anti-PD-L1/TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine in previously untreated patients with locally advanced or metastatic pancreatic cancer: A multicenter, phase Ib/II study
Presenter: Jiajia Yuan
Session: Poster session 18
Resources:
Abstract